UNION KOREA PHARM CO.,Ltd Logo

UNION KOREA PHARM CO.,Ltd

Develops and manufactures prescription drugs like antibiotics and analgesics for global markets.

080720 | KO

Overview

Corporate Details

ISIN(s):
KR7080720006
LEI:
Country:
South Korea
Address:
강원도 원주시 문막읍 문막공단길 246, 원주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Union Korea Pharm Co., Ltd. is a pharmaceutical company specializing in the research, development, production, and sale of prescription drugs. The company manufactures a range of specialty medicines, including antibiotics, anti-inflammatory analgesics, and skeletal muscle relaxants. Its products are available in various formulations such as solid dosage forms, liquid injections, and powder injections. Union Korea Pharm operates under strict quality control and Good Manufacturing Practice (GMP) standards. While its primary market is South Korea, the company also engages in international business, aiming to provide total healthcare solutions as a comprehensive bio-company.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Legal Proceedings Report
회생절차개시결정
Korean 8.0 KB
2025-09-16 00:00
Delisting Announcement
주권매매거래정지기간변경 (회생절차 개시결정)
Korean 5.4 KB
2025-09-15 00:00
Legal Proceedings Report
횡령ㆍ배임혐의진행사항
Korean 6.4 KB
2025-09-11 00:00
Capital/Financing Update
사채원리금미지급발생
Korean 8.7 KB
2025-09-10 00:00
Legal Proceedings Report
[기재정정]주요사항보고서(회생절차개시신청)
Korean 8.8 KB
2025-09-09 00:00
Legal Proceedings Report
주요사항보고서(회생절차개시신청)
Korean 5.5 KB
2025-09-09 00:00
Delisting Announcement
주권매매거래정지기간변경 (회생절차 개시신청)
Korean 5.4 KB
2025-09-02 00:00
Legal Proceedings Report
횡령ㆍ배임혐의진행사항
Korean 6.4 KB
2025-09-01 00:00
Legal Proceedings Report
횡령ㆍ배임혐의진행사항
Korean 7.5 KB
2025-09-01 00:00
Legal Proceedings Report
횡령ㆍ배임혐의진행사항
Korean 7.4 KB
2025-08-29 00:00
Legal Proceedings Report
횡령ㆍ배임혐의진행사항
Korean 7.1 KB
2025-08-29 00:00
Legal Proceedings Report
횡령ㆍ배임혐의진행사항
Korean 6.9 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-08-13 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.3 KB
2025-08-11 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB

Automate Your Workflow. Get a real-time feed of all UNION KOREA PHARM CO.,Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for UNION KOREA PHARM CO.,Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for UNION KOREA PHARM CO.,Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB

Talk to a Data Expert

Have a question? We'll get back to you promptly.